EcoDrugPlus

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSBSLG00000012864
Gene Symbol: PSMA4
3 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSBSLG00000013454
Gene Symbol: PSMA5
2 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSBSLG00000018536
Gene Symbol: PSMA6
3 Cross references
229 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSBSLG00000025729
Gene Symbol: PSMA8
3 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSBSLG00000011153
Gene Symbol: PSMB1
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSBSLG00000020317
Gene Symbol: PSMB2
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSBSLG00000014211
Gene Symbol: PSMB3
1 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSBSLG00000006949
Gene Symbol: PSMB4
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSBSLG00000002158
Gene Symbol: PSMB6
3 Cross references
228 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSBSLG00000004898
Gene Symbol: PSMB7
1 Cross references
188 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSBSLG00000013233
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSBSLG00000022372
Gene Symbol: PSMC1
3 Cross references
318 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).